ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The French drugmaker Sanofi has named Boehringer Ingelheim a partner for the manufacture of therapeutic monoclonal antibodies. Under the deal, Sanofi will have access to capacity at Boehringer’s Biberach, Germany, plant, one of the world’s largest biologics production sites. Sanofi notes that 72% of its R&D projects are in biologics, and half of those are monoclonal antibodies. Separately, Sanofi has agreed to use Catalent Pharma Solutions’ SMARTag technology to develop antibody-drug conjugates. Catalent claims the technology yields ADCs with improved toxicity profiles.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter